RTI Surgical Inc (NASDAQ:RTIX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. RTI Surgical Inc is a surgical implant company. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera, dermal tissue and bovine and porcine animal tissue. RTI Surgical Inc has a market cap of $349.980 million; its shares were traded at around $5.62 with and P/S ratio of 1.38.
For the last quarter RTI Surgical Inc reported a revenue of $71.2 million, compared with the revenue of $70.82 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $280.9 million, an increase of 0.5% from last year. For the last five years RTI Surgical Inc had an average revenue growth rate of 5.6% a year.
The reported loss per diluted share was 5 cents for the year, compared with the earnings per share of $-0.31 in the previous year. The RTI Surgical Inc had an operating margin of 2.31%, compared with the operating margin of 2.69% a year before. The 10-year historical median operating margin of RTI Surgical Inc is 3.55%. The profitability rank of the company is 6 (out of 10).
At the end of the fiscal year, RTI Surgical Inc has the cash and cash equivalents of $10.9 million, compared with $22.4 million in the previous year. The company had no long term debt, compared with $42.1 million in the previous year. RTI Surgical Inc has a financial strength rank of 7 (out of 10).
At the current stock price of $5.62, RTI Surgical Inc is traded at 29.8% premium to its historical median P/S valuation band of $4.33. The P/S ratio of the stock is 1.38, while the historical median P/S ratio is 1.09. The stock gained 20.22% during the past 12 months.
For the complete 20-year historical financial data of RTIX, click here.
No comments:
Post a Comment